Patients with BRAF V600–mutated stage III melanoma received 1 year of adjuvant dabrafenib plus trametinib or placebo. After more than 8 years, the risk of death was 20% lower with treatment, but the ...
ATHENS, Greece — Real-world data confirm that complete nodal dissection following a positive sentinel lymph node biopsy in patients with stage III melanoma and micrometastases does not significantly ...
CHICAGO (WLS) -- An estimated one in five Americans will be diagnosed with skin cancer in their lifetime, and one person dies from melanoma - the deadliest form of skin cancer - every hour. There have ...
SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback